# A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC

> **NCT04331743** · PHASE1 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** Liposome-entrapped Mitoxantrone Hydrochloride Injection

## Key facts

- **NCT ID:** NCT04331743
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-05
- **Primary completion:** 2023-05-15
- **Final completion:** 2023-06-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2021-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04331743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04331743, "A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04331743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*